About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: OREX
- CUSIP: 68616410
- Previous Close: $4.44
- 50 Day Moving Average: $3.88
- 200 Day Moving Average: $3.14
- 52-Week Range: $14,586,000.00 - $1.65
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.66
- P/E Growth: 0.01
- Market Cap: $64.76M
- Outstanding Shares: 14,586,000
- Beta: 2.72
- Net Margins: -71.59%
- Return on Equity: -354.92%
- Return on Assets: -29.11%
Companies Related to Orexigen Therapeutics:
- Debt-to-Equity Ratio: 2.74%
- Current Ratio: 4.17%
- Quick Ratio: 3.81%
What is Orexigen Therapeutics' stock symbol?
Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."
Where is Orexigen Therapeutics' stock going? Where will Orexigen Therapeutics' stock price be in 2017?
5 analysts have issued 1-year target prices for Orexigen Therapeutics' stock. Their predictions range from $1.00 to $2.00. On average, they anticipate Orexigen Therapeutics' share price to reach $1.50 in the next twelve months.
When will Orexigen Therapeutics announce their earnings?
Orexigen Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns Orexigen Therapeutics stock?
Orexigen Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baupost Group LLC MA (15.27%), Foresite Capital Management II LLC (3.72%), Foresite Capital Management III LLC (1.74%) and Old West Investment Management LLC (1.41%).
Who bought Orexigen Therapeutics stock? Who is buying Orexigen Therapeutics stock?
Orexigen Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Old West Investment Management LLC.
How do I buy Orexigen Therapeutics stock?
Shares of Orexigen Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Orexigen Therapeutics stock cost?
One share of Orexigen Therapeutics stock can currently be purchased for approximately $4.44.